期刊文献+

3-(苄氧基)-4-氧代-4H-吡喃-2-羧酸的合成工艺优化

Improved synthetic process of 3-(benzyloxy)-4-oxo-4H-pyran-2-carboxylic acid
原文传递
导出
摘要 目的制备3-(苄氧基)-4-氧代-4H-吡喃-2-羧酸,并对其合成工艺进行优化。方法以麦芽酚为起始原料,经取代和加成反应制得3-(苯氧基)-2-(2-羟基-2-苯乙基)-4H-呋喃-4-酮,再经取代、消除、氧化制得3-(苄氧基)-4-氧代-4H-吡喃-2-羧酸。结果与结论反应总收率为77.90%,纯度为99.95%,该化合物的合成路线优化后具备操作简便、反应条件温和、原料易得等优点,更适合产业化。 An improved synthetic process of the key intermediate of 3-(benzyloxy)-4-oxo-4H-pyran-2-carboxylic acid was described.The compound was prepared from 3-hydroxy-2-methyl-4H-pyran-4-one,after substitution with benzyl bromide,condensation reaction with benzaldehyde,followed by substitution and elimination reaction with thionyl chloride,then oxidation reaction with sodium periodate and sodium hypochlorite respectively to get the final product.The total yield of the process was 77.90%,and the purity was 99.95%.The starting materials and reagents are commercially available,and the process was easy to work up.
作者 蒋港龙 马潇 李国靖 王慧莹 李建其 刘育 JIANG Gang-long;MA Xiao;LI Guo-jing;WANG Hui-ying;LI Jian-qi;LIU Yu(Novel Technology Center of Pharmaceutical Chemistry,Shanghai Institute of Pharmaceutical Industry,China State institute of Pharmaceutical Industry,Shanghai 201203,China;Shanghai Engineering Research Center of pharmaceutical Process,Shanghai 201203,China;College of Chemistry and Chemical Engineering,Shanghai University of Engineering Science,Shanghai 201203,China)
出处 《中国药物化学杂志》 CAS CSCD 2022年第3期204-207,共4页 Chinese Journal of Medicinal Chemistry
关键词 3-(苄氧基)-4-氧代-4H-吡喃-2-羧酸 工艺优化 度鲁特韦 巴洛沙韦酯 3-(benzyloxy)-4-oxo-4H-pyran-2-carboxylic acid process improvement dolutegravir baloxavir marboxil
  • 相关文献

参考文献2

二级参考文献4

  • 1李佳悦(编译),刘洋(审校).巴洛沙韦[J].中国药物化学杂志,2019,29(5):411-411. 被引量:5
  • 2ViiVHealthcare.Dolutegravir[EB/OL].[2013-8-12].http://www.accessdata.fda.gov/drugsatfda——docs/label/2013/2047901b1.pdf.
  • 3ViiVHealthcare.Dolutegravir[-EB/OL].[2013-8-12].http://www.accessdata.fda.gov/drugsatfda——docs/nda/2013/2047900riglS000SumR.pdL.
  • 4ViiVHealthcare.Dolutegravir[EB/OL].[2013-8-12].http://www.accessdata.fda.gov/drugsatfda-docs/nca/2013/2047900rigls000PharmR.pdf.

共引文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部